IVF Lite: a smart IVF programme based on mild ovarian stimulation for good prognosis patients

Gianaroli, Luca; Vitagliano, Amerigo; Ferraretti, Anna Pia; Azzena, Silvia; Terzuoli, Gaia; Perruzza, Davide; Ambrosini, Guido; Tabanelli, Carla; Magli, M. Cristina

doi:10.1016/j.rbmo.2022.04.003

Cited by 5 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The implantation rate was the ratio between the number of gestational sacs with FHB and the number of transferred embryos. A miscarriage is a pregnancy loss occurring before the 20th gestational week [ 2 ].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study

D’Amato¹,

Caringella²,

Stanziano³

et al. 2023

Diagnostics

Self Cite

View full text Add to dashboard Cite

Background: In recent times, different novel GnRH-antagonist protocols with various combinations of gonadotropins and other molecules (e.g., aromatase inhibitors, selective estrogen receptor modulators) have been proposed for expected normal ovarian responders undergoing assisted reproductive treatments. The purpose of this study was to evaluate the effectiveness of a novel ovarian stimulation protocol based on the combination of corifollitropin-alfa plus five days of letrozole in E-NOR women undergoing IVF as compared with a daily recombinant-FSH regimen. Methods: We conducted a retrospective-controlled study on 182 couples undergoing their first IVF attempt. In Group A (experimental), letrozole (2.5 mg daily) was administered from day 2 (up to day 6 of the cycle), followed by corifollitropin-alfa on day 3 and daily recombinant FSH from day 10. In Group B, recombinant FSH from day 2 were administered (150 IU-225 IU daily). Statistical analysis was completed using SPSS Statistics. The primary outcome was the total number of MII oocytes retrieved. Results: Group A showed similar results compared to Group B in terms of MII oocytes, live birth, implantation, and clinical pregnancy rates (p = ns). Nevertheless, the experimental group was associated with a trend towards a higher number of developing follicles, total oocytes, and embryos (p < 0.05) with lower estradiol and progesterone values at ovulation induction compared to Group B, resulting in an increased chance of performing a fresh embryo transfer (p < 0.05). Conclusions: The combination of CFα plus five days of letrozole was associated with a trend towards a higher number of developing follicles, total oocytes, and obtained embryos. Moreover, the experimental protocol resulted in lower estradiol and progesterone values at ovulation induction compared to daily rFSH, with an increased chance of performing a fresh embryo transfer (with no OHSS occurrence). Given the observational design of our study, further well-conducted RCTs are needed.

show abstract

Section: Methodsmentioning

confidence: 99%

“…As the demand for IVF treatments continues to increase globally, the need for safe and effective ovarian stimulation protocols has become an essential aspect of reproductive medicine [ 1 , 2 ]. E-NOR patients, who account for approximately one-third of IVF cases, are a crucial group in this regard.…”

Section: Introductionmentioning

confidence: 99%

Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study

D’Amato¹,

Caringella²,

Stanziano³

et al. 2023

Diagnostics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Promoters of these protocols emphasize that, in addition to lowering the costs for the patients and society, they reduce patient discomfort and risk of ovarian hyperstimulation syndrome (OHSS), therefore reducing dropout rates. As a result, some studies indicate that, when considering the cumulative live birth rate per woman, these 'lite' treatments can be successful in more than two-thirds of cases (Ferraretti et al, 2015;Gianaroli et al, 2022).…”

Section: Pricing Strategies and Treatment Affordabilitymentioning

confidence: 99%

Biomedical Innovation in Fertility Care

Perrotta

2024

View full text Add to dashboard Cite

“…Há na literatura, estudos que corroboram o uso da estimulação ovariana mínima como uma alternativa em pacientes com baixa reserva ovariana ou hiporrespondedoras 24,25,26,27 . Os resultados deste presente estudo, que foi realizado em pacientes de bom prognóstico e boa reserva ovariana (contagem de folículos antrais média de 12.26 ± 5.28 no grupo convencional e 13.20 ± 5.79 no grupo com baixas doses de gonadotrofina sem diferença estatística entre os grupos; p=0.421), dão suporte aos estudos que afirmam que este protocolo também pode ser oferecido para pacientes normo e/ou hiperrespondedoras 19,28 sem prejuízo no resultado clínico de taxa de gravidez.…”

Section: Riscos E Benefíciosunclassified

Estimulação ovariana mínima: protocolo de Fertilização in Vitro com baixas doses de gonadotrofinas para atender casais inférteis de bom prognóstico em centro universitário de reprodução humana

Nakano¹

View full text Add to dashboard Cite

IVF Lite: a smart IVF programme based on mild ovarian stimulation for good prognosis patients

Cited by 5 publications

References 23 publications

Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study

Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study

Biomedical Innovation in Fertility Care

Estimulação ovariana mínima: protocolo de Fertilização in Vitro com baixas doses de gonadotrofinas para atender casais inférteis de bom prognóstico em centro universitário de reprodução humana

Contact Info

Product

Resources

About